Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.23M, -58.9% YoY · Filed Aug 19, 2026
Jaguar Health, Inc. (JAGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.2 million and a net loss of $12.8 million. As of Jun 30, 2026 it held $3.8 million in cash and investments and $1.1 million in total debt.
Revenue
$1.23M
-58.9% vs year-ago quarter
Net income
$-12.80M
-21.2% vs year-ago quarter
Operating cash flow
$-5.34M
+13.8% vs year-ago quarter
Free cash flow
$-7.83M
-23.4% vs prior quarter
EPS
$-15.70
+95.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
171.35M
+1086.6% vs year-ago quarter
Net cash
$2.70M
Q2 FY2026
Operating margin
-93.1%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JAGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1585608
- Former names
- Jaguar Animal Health, Inc. (until Jul 31, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $20.3M | $3.2M | $3.1M | $3.0M |
| Operating income | -$7.6M | $10.2M | -$21.2M | -$7.2M | -$8.0M |
| Net income | -$12.8M | $8.7M | -$23.2M | -$9.6M | -$10.6M |
| Diluted EPS | -$15.70 | -$13.60 | -$4.41 | -$6.28 | -$358.94 |
| Operating cash flow | -$5.3M | $8.8M | -$5.5M | -$4.7M | -$6.2M |
| Total assets | $34.2M | $37.4M | $38.3M | $49.5M | $48.3M |
| Total liabilities | $29.3M | $53.2M | $57.0M | $45.1M | $41.4M |
| Stockholders' equity | $4.9M | -$15.8M | -$18.7M | $4.4M | $6.9M |
| Cash and investments | $3.8M | $7.3M | $968,000 | $3.5M | $2.2M |
| Total debt | $1.1M | $1.2M | $1.1M | $1.1M | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 3, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 28, 2026 | Sep 25, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale, Other events
|
Sep 25, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Sep 24, 2026 | Sep 23, 2026 |
All 1004 Jaguar Health, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.